HN2006004827A - Nueva forma de sal de un agonista de dopamina - Google Patents

Nueva forma de sal de un agonista de dopamina

Info

Publication number
HN2006004827A
HN2006004827A HN2006004827A HN2006004827A HN2006004827A HN 2006004827 A HN2006004827 A HN 2006004827A HN 2006004827 A HN2006004827 A HN 2006004827A HN 2006004827 A HN2006004827 A HN 2006004827A HN 2006004827 A HN2006004827 A HN 2006004827A
Authority
HN
Honduras
Prior art keywords
salt form
dopamine agonist
new salt
new
dopamine
Prior art date
Application number
HN2006004827A
Other languages
English (en)
Inventor
Peter Green Stuart
Alain Lazzari Oliver
Charles Miller Duncan
Henri Salingue Fabrice
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of HN2006004827A publication Critical patent/HN2006004827A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invencion se refiere a una nueva forma de sal del agonista de dopamina 5-[(2R,5S)-5-metil-4-propilmorfolin-2-il]piridin -2-amina.
HN2006004827A 2005-02-07 2006-02-03 Nueva forma de sal de un agonista de dopamina HN2006004827A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502509.3A GB0502509D0 (en) 2005-02-07 2005-02-07 Novel salt form of a dopamine agonist

Publications (1)

Publication Number Publication Date
HN2006004827A true HN2006004827A (es) 2010-06-09

Family

ID=34355919

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2006004827A HN2006004827A (es) 2005-02-07 2006-02-03 Nueva forma de sal de un agonista de dopamina

Country Status (26)

Country Link
US (1) US7498329B2 (es)
EP (1) EP1848709B1 (es)
JP (1) JP4157158B2 (es)
KR (1) KR100997033B1 (es)
CN (1) CN101115737B (es)
AR (1) AR053122A1 (es)
AT (1) ATE509924T1 (es)
AU (1) AU2006211033A1 (es)
BR (1) BRPI0608149A2 (es)
CA (1) CA2595815C (es)
DO (1) DOP2006000030A (es)
ES (1) ES2364345T3 (es)
GB (1) GB0502509D0 (es)
GT (1) GT200600040A (es)
HN (1) HN2006004827A (es)
IL (1) IL184395A0 (es)
MX (1) MX2007008462A (es)
NL (1) NL1031087C2 (es)
NZ (1) NZ556292A (es)
PA (1) PA8662001A1 (es)
PE (1) PE20061034A1 (es)
RU (1) RU2393153C2 (es)
TW (1) TWI314930B (es)
UY (1) UY29365A1 (es)
WO (1) WO2006082511A1 (es)
ZA (1) ZA200605491B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8522799B2 (en) * 2005-12-30 2013-09-03 Lam Research Corporation Apparatus and system for cleaning a substrate
KR100913791B1 (ko) * 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
PT3150610T (pt) 2010-02-12 2019-11-11 Pfizer Sais e polrmorfos de 8-fluor0-2-{4- [(metilamino}metil]fenil}-1,3,4,5-tetrahidr0-6hazepin0[ 5,4,3-cd]indol-6-0na
EP3212637B1 (en) 2014-10-31 2021-06-02 Indivior UK Limited Dopamine d3 receptor antagonists compounds
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
RU2622018C1 (ru) * 2016-06-16 2017-06-08 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Быстро растворяющаяся трансбуккальная плёнка для лечения депрессивных расстройств, тревоги и расстройств адаптации

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889775B2 (ja) * 2002-12-10 2007-03-07 ファイザー・インク Ｉ．ａ．性機能障害の治療においてドパミンアゴニストとして使用するためのモルホリン誘導体
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
MXPA06013786A (es) * 2004-05-27 2007-01-25 Pfizer Nuevos derivados de aminopiridina y su uso como farmacos.

Also Published As

Publication number Publication date
CN101115737B (zh) 2010-12-01
PA8662001A1 (es) 2006-09-08
CA2595815A1 (en) 2006-08-10
US7498329B2 (en) 2009-03-03
EP1848709A1 (en) 2007-10-31
TWI314930B (en) 2009-09-21
US20060183740A1 (en) 2006-08-17
CA2595815C (en) 2010-07-27
AU2006211033A1 (en) 2006-08-10
WO2006082511A1 (en) 2006-08-10
TW200639164A (en) 2006-11-16
EP1848709B1 (en) 2011-05-18
JP4157158B2 (ja) 2008-09-24
NZ556292A (en) 2010-10-29
AR053122A1 (es) 2007-04-25
NL1031087A1 (nl) 2006-08-08
KR20070094647A (ko) 2007-09-20
RU2393153C2 (ru) 2010-06-27
CN101115737A (zh) 2008-01-30
UY29365A1 (es) 2006-10-02
RU2007130150A (ru) 2009-03-20
DOP2006000030A (es) 2006-08-15
ATE509924T1 (de) 2011-06-15
KR100997033B1 (ko) 2010-11-26
BRPI0608149A2 (pt) 2009-11-10
GT200600040A (es) 2007-01-12
IL184395A0 (en) 2007-10-31
JP2008529997A (ja) 2008-08-07
GB0502509D0 (en) 2005-03-16
PE20061034A1 (es) 2006-10-19
ES2364345T3 (es) 2011-08-31
ZA200605491B (en) 2008-09-25
NL1031087C2 (nl) 2007-01-19
MX2007008462A (es) 2007-07-25

Similar Documents

Publication Publication Date Title
CR20110432A (es) Pirimidinas fusionadas
ECSP088341A (es) Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida
HN2006004827A (es) Nueva forma de sal de un agonista de dopamina
CY1111793T1 (el) Μυκητοκτονες συνθεσεις
UA107791C2 (en) Pesticidal compositions
GT200700002S (es) Cubierta de recipiente
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
DK1813614T3 (da) Cytotoksiske midler, der omfatter nye tomaymycinderivater
DE502008000766D1 (de) Blasmaschine mit Garniturteilhalter, sowie Garniturteilhalter
CR10353A (es) Nuevos compuestos.
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
CR9344S (es) Regadera
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
IT1391614B1 (it) Cilindro, particolarmente cilindro emettitore di un dispositivo di comando idraulico di innesto.
EA201101228A1 (ru) Тампон
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina
ECSP10010491A (es) Composiciones fungicidas con 3'-bromo-2,3,4,6'-tetrametoxi-2',6-dimetilbenzofenona
UY32711A (es) Nueva forma cristalina de pemirolast
SV2009003315A (es) Nueva utilizacion para el tratamiento de las leucemias
ITPN20080006A1 (it) "macchina lava-asciuga pavimenti perfezionata".
FR2905053B1 (fr) Chaussure impermeable.
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
NL2002065A1 (nl) Oogstmachine.
ITMI20060637A1 (it) Macchina circolare per maglieria o per calzetteria o simile a doppio cilindro